QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.68
-1.42 (-5.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close28.10
Open28.13
Bid0.00 x 1100
Ask0.00 x 900
Day's Range26.25 - 28.76
52 Week Range13.71 - 43.23
Volume310,912
Avg. Volume284,959
Market Cap993.71M
Beta (3Y Monthly)-0.65
PE Ratio (TTM)N/A
EPS (TTM)-2.47
Earnings DateMay 30, 2017 - Jun 2, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.22
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 18, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented non-clinical data demonstrating that a next-generation synthetic promoter developed for liver-directed gene therapy is able to drive gene expression at increased levels and with very high specificity, allowing uniQure to tailor expression levels required for a specific therapeutic transgene.  These data were featured in an oral session at the 26th Congress of the European Society of Gene and Cell Therapy (ESGCT), being held from October 16 – 19, in Lausanne, Switzerland. A “promoter” is an essential component of a gene therapy construct that controls expression of a therapeutic protein.  Most gene therapies incorporate natural promoters, which have limitations and may not optimize the expression of genes in specific target cells.

  • GlobeNewswire5 days ago

    uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

    ~ Commercial Capacity for AAV Gene Therapy Production Significantly Enhanced by Highly Scalable 500 Liter Reactors ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 17,.

  • GlobeNewswire6 days ago

    uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

    ~ New Data Further Demonstrating Leading Gene Therapy Manufacturing and Administration Capabilities ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 16, 2018 -- uniQure.

  • GlobeNewswire24 days ago

    uniQure to Participate in Multiple Upcoming Industry Conferences

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 28, 2018-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced ...

  • GlobeNewswire28 days ago

    uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

    LEXINGTON, Mass and AMSTERDAM, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) --  uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs,  today announced that the third patient has been treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicine (PRIME) regulatory initiative by the European Medicines Agency. The Phase IIb dose-confirmation study is an open-label, single-arm, single-dose trial being conducted in the United States to confirm the dose of AMT-061 prior to patient treatment in the ongoing Phase III HOPE-B pivotal trial.

  • Analyzing uniQure’s Valuation Trend
    Market Realistlast month

    Analyzing uniQure’s Valuation Trend

    Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.

  • uniQure: Its Promising Research Pipeline
    Market Realistlast month

    uniQure: Its Promising Research Pipeline

    It has a collaboration with Bristol-Myers Squibb (BMY) that’s targeted at cardiovascular disease. AMT-130 has received orphan drug designation in the United States and orphan medicinal product designation from the European Medicines Agency.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realistlast month

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • Implied Volatility Surging for uniQure (QURE) Stock Options
    Zackslast month

    Implied Volatility Surging for uniQure (QURE) Stock Options

    Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    Achillion Appoints Paul Firuta Chief Operating Officer

    Achillion Pharmaceuticals, Inc. (ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and Chief Operating Officer effective immediately. “Paul’s operational leadership and successful track record launching rare disease treatments, including the complement inhibitor Cinryze®, will greatly benefit Achillion as we accelerate our factor D clinical programs and prepare for registrational trials and commercialization,” commented Joseph Truitt, President and Chief Executive Officer of Achillion.

  • GlobeNewswire2 months ago

    uniQure to Participate at Multiple Upcoming Conferences

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced ...

  • Play The Future of Gene Therapy With These 5 Biotech Stocks
    InvestorPlace2 months ago

    Play The Future of Gene Therapy With These 5 Biotech Stocks

    Innovation has always been the mantra when it comes to biotech stocks. Gene therapy is quickly becoming the technique du jour for curing orphan and rare diseases. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight the faulty ones, replacing/editing missing/broken prices or actually “turning off” the genes causing problems.

  • GlobeNewswire2 months ago

    uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 23, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.  AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency. “The initiation of the AMT-061 dose-confirmation study is an important step toward our goal of advancing a potentially life-changing treatment for patients with hemophilia B,” said Robert Gut, M.D., Ph.D., chief medical officer of uniQure.  “I am extremely proud of the efforts made by the uniQure team to initiate this study, the objective of which is to demonstrate meaningful increases in FIX activity using the Padua variant and confirm dosing for the HOPE-B pivotal trial initiated this past June.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree ...

  • UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of 8.06% and -9.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    UniQure: 2Q Earnings Snapshot

    The Amsterdam-based company said it had a loss of 57 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire2 months ago

    uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress

    ~Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061. ~First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061. ~Robert Gut, M.D., Ph.D., Named ...

  • 3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure
    Investor's Business Daily3 months ago

    3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure

    Gene therapy companies are looking to advance the technology, creating potentially curative treatments for genetic diseases.

  • Benzinga4 months ago

    3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

    Uniqure NV (NASDAQ: QURE ), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. The Analyst B. Riley ...

  • Are These 3 Red-Hot Gene Therapy Stocks Still Buys?
    Motley Fool4 months ago

    Are These 3 Red-Hot Gene Therapy Stocks Still Buys?

    Is continued success in the cards for these biotech stocks?

  • ACCESSWIRE5 months ago

    Wired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in Chicago

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on uniQure N.V. (NASDAQ: QURE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=QURE as the Company's latest news hit the wire. On May 18, 2018, the Company announced that it has reported preclinical data in three poster presentations highlighting its expertise in efficient transduction of target cells within affected organs at American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting held in Chicago, Illinois, May 17-18, 2018. The presentations highlighted that uniQure's modular platform is now broadly applicable to treat patients with both liver and central nervous system (CNS) disorders.